Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome
January 23, 2025 08:30 ET
|
Quoin Pharmaceuticals, Inc.
Four Weeks After Discontinuation of Treatment with QRX003 Complete Reversal of Positive Clinical Improvements Across all Measured Endpoints ObservedData Supports QRX003 Mechanism of Action as a...
Delta-like Ligand 3 (DLL3) Targeted Therapies Market Research 2025: 1 Drug, Imdelltra (Tarlatamab) Available / 10 Drugs by Company, Indication and Phase / Approved Drug Dosage, Sales & Pricing Insight
January 23, 2025 07:51 ET
|
Research and Markets
Dublin, Jan. 23, 2025 (GLOBE NEWSWIRE) -- The "DLL3 Targeted Therapies Market, Approved Drugs, Dosage, Pricing & Clinical Trials Insight 2025" report has been added to ResearchAndMarkets.com's...
NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
January 21, 2025 16:20 ET
|
NurExone Biologic Inc
NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
January 21, 2025 09:00 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Adaptive Research Expands into Psychiatry with Addition of Prodigy Psychiatric Group to Clinical Trial Network
January 21, 2025 08:30 ET
|
Adaptive Research Inc
Adaptive Research announced that Prodigy Psychiatric Group has joined its clinical trial network, marking Adaptive Research's expansion into psychiatry.
PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel
January 20, 2025 08:55 ET
|
PharmAla Biotech
PharmAla partners with Merhavim and MAPS Israel for innovative MDMA PTSD clinical trial data sharing partnership in wake of Gaza Ceasefire
Clinical Trial Imaging Market Size to Reach USD 2.45 Billion by 2032, Growing at a CAGR of 7.86% - SNS Insider
January 15, 2025 09:37 ET
|
SNS Insider pvt ltd
Pune, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Clinical Trial Imaging Market Size & Growth Analysis “According to SNS Insider, The Clinical Trial Imaging Market was estimated at USD 1.24 billion in...
Yseop Kicks Off 2025 by Strengthening Its Leadership in Generative AI for Life Sciences
January 15, 2025 09:00 ET
|
Yseop
NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Yseop, a global leader in Generative AI for life sciences, is starting 2025 with a series of achievements and strategic collaborations that underscore its...
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Global Clinical Trials Review: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status
January 15, 2025 07:22 ET
|
Research and Markets
Dublin, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The "Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) - Global Clinical Trials Review, 2024" clinical trials has been added to ...
Attralus Announces Enrollment of First Patient in Phase 3 Trial for the Pan-Amyloid Diagnostic 124I-evuzamitide (AT-01) for Cardiac Amyloidosis
January 15, 2025 07:00 ET
|
Attralus, Inc
Phase 3 – REVEAL study for iodine 124I-evuzamitide (AT-01) in patients with suspected cardiac amyloidosis has begun enrollment by Brigham and Women’s Hospital, Boston MA, in conjunction with...